Timolol

Generic Name: Timolol

Brand Names: Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₄N_₄O_₃S

CAS Number: 26839-75-8

Unique Ingredient Identifier: 5JKY92S7BR

Background: Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

Indication: Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.

Associated Conditions: Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)

Clinical Trials

Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension
Drug: Brinzolamide 1% ophthalmic suspension
Drug: Timolol 0.5% ophthalmic solution

First Posted Date: 2011-05-20

Last Posted Date: 2014-04-10

Lead Sponsor: Alcon Research

Target Recruit Count: 328

Registration Number: NCT01357616

DE-111 Against Timolol Ophthalmic Solution 0.5%

Phase 3

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Timolol ophthalmic solution 0.5%
Drug: DE-111 ophthalmic solution
Drug: Placebo ophthalmic solution

First Posted Date: 2011-04-26

Last Posted Date: 2015-07-10

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 166

Registration Number: NCT01342094

Locations: 🇯🇵
Santen study sites, Osaka, Japan

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Phase 3

Completed

Conditions: Ocular Hypertension
Open-angle Glaucoma

Interventions: Drug: Timolol and Tafluprost
Drug: Fixed Dose Combination of tafluprost and timolol

First Posted Date: 2011-03-01

Last Posted Date: 2012-06-08

Lead Sponsor: Santen Oy

Target Recruit Count: 401

Registration Number: NCT01306461

AR-12286 in Combination With Latanoprost

Phase 2

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprost 0.005%
Drug: AR-12286 Ophthalmic Solution 0.5%
Drug: Timolol maleate ophthalmic solution 0.5%

First Posted Date: 2011-02-24

Last Posted Date: 2014-05-08

Lead Sponsor: Aerie Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT01302249

Locations: 🇺🇸
Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States
🇺🇸
Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States
🇺🇸
David Silverstone, M.D., New Haven, Connecticut, United States

and more 12 locations

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: DE-112
Drug: DE-112 Vehicle Solution
Drug: Timolol Maleate Solution

First Posted Date: 2011-01-19

Last Posted Date: 2012-12-17

Lead Sponsor: Santen Inc.

Target Recruit Count: 147

Registration Number: NCT01279083

Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel

Phase 3

Conditions: Melanoma

Interventions: Drug: Timolol + LCP
Device: LCP

First Posted Date: 2011-01-10

Last Posted Date: 2012-03-26

Lead Sponsor: Centre Hospitalier Universitaire de Nice

Target Recruit Count: 44

Registration Number: NCT01272609

Locations: 🇫🇷
CHU de Nice - 4 avenue Reine Victoria, Nice, Alpes-Maritimes, France
🇫🇷
CHU de Dijon, Dijon, France
🇫🇷
CH de Quimper, Quimper, France

and more 7 locations

Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Preservative-Free Tafluprost or vehicle
Drug: Preservative-Free Timolol maleate

First Posted Date: 2010-12-06

Last Posted Date: 2018-09-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 190

Registration Number: NCT01254604

Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

Phase 4

Withdrawn

Conditions: Benign Vascular Periocular Lesions

Interventions: Drug: topical Timolol

First Posted Date: 2010-11-30

Last Posted Date: 2012-10-30

Lead Sponsor: Loyola University

Registration Number: NCT01250457

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Not Applicable

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution
Drug: brimonidine tartrate ophthalmic solution
Other: fixed combination vehicle
Drug: timolol ophthalmic solution

First Posted Date: 2010-10-27

Last Posted Date: 2012-09-14

Lead Sponsor: Allergan

Target Recruit Count: 238

Registration Number: NCT01229462

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Phase 1

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: AGN-207281 vehicle ophthalmic solution (Placebo)
Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
Drug: timolol ophthalmic solution 0.5%

First Posted Date: 2010-10-07

Last Posted Date: 2015-08-17

Lead Sponsor: Allergan

Target Recruit Count: 50

Registration Number: NCT01215786

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy